Treatments used to prevent and treat male pattern baldness, the difficulty in finding a permanent cure for hair loss, and the potential financial motivations of companies not wanting to find a cure.
HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
A user's successful hair regrowth after 7 months of using 5% minoxidil, 1mg finasteride, and adding micro needling 4 months ago. The user also took biotin, fish oil, and collagen supplements, and reduced finasteride intake to once every 3 days due to minor libido decay.
Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.
Hair loss is primarily genetic, and nutrient deficiencies are unlikely to be the cause. DHT inhibitors can slow hair loss, but concerns about side effects are common.
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
The conversation is about choosing between gray market Pyrilutamide and the official Kintor version for hair loss treatment. Users share mixed experiences, with some finding both versions effective and others not seeing results.
The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
The user switched from prescribed topical minoxidil and finasteride to stronger grey market alternatives, hoping for better hair growth but experiencing shedding. Concerns were raised about the legitimacy and safety of grey market products, with suggestions to use prescribed medications instead.
PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.
Breezula's effectiveness may depend on the vehicle used for its application, with concerns about the grey market version's formulation. Phase 3 results are promising, but skepticism remains about the grey market product's authenticity and effectiveness.
PP405 is being discussed for hair regrowth, with mixed opinions on its effectiveness and legitimacy. Some users report early signs of regrowth, while others are skeptical about its authenticity and results.
The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.
The conversation is about which blood markers to test before starting a 5-AR inhibitor for hair loss. The user mentions already testing Total T, Free T, SHBG, Estradiol, Haematocrit, Red blood cell count, and White cell count, and asks if DHT or additional markers are needed.
Breezula, a hair loss treatment, is expected to cost around $100 a month and is anticipated to be released in 2026. The effectiveness of Breezula is debated, with some suggesting it loses effectiveness over time and others arguing it maintains hair compared to baseline.
The user experienced reduced hair loss using grey-market KX-826 alongside Minoxidil foam, achieving better results with Minoxidil liquid but restricted to foam due to an allergy. Initial side effects included shortness of breath, racing heart, and dizziness, which subsided after the first week.
The conversation is about which blood tests are essential to check before starting hair loss treatment with finasteride or dutasteride. The tests mentioned include DHT, PSA, Estrogen/Estradiol, Testosterone, FSH, and LH.
Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.
People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
The conversation discusses the effectiveness of official and gray market Pyrilutamide for hair loss. One user experienced chest pain with the gray market version, while another found the official Koshine version mildly effective.
People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.
The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
People discuss using various shampoos and conditioners to make hair look thicker, mentioning products like Nizoral, Redken, Nioxin, hims thick fix, and purador. Some users highlight ingredients like Redensyl and Baicapil, while others note that shampoos and conditioners aid in hair care but not in hair growth.
The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.
The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.